Apr 01, 2019
Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor
Mar 28, 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Feb 07, 2019
CStone and IMPACT Therapeutics' clinical collaboration progresses to IND filing acceptance for CS1001+IMP4297 combination therapy
Nov 18, 2018
CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China
Nov 12, 2018
Immune Checkpoint Inhibitors Market, 2022 - Opdivo and Keytruda Presents Significant Growth Opportunity
Oct 23, 2018
CStone Receives US FDA IND Approval for Recombinant PD-1 mAb CS1003
Oct 23, 2018
Global Checkpoint Inhibitors Markets 2018-2023 with Profiles of Agenus, BeiGene, BIOCAD, Forty Seven, Seattle Genetics, Shanghai Cell Therapy, Tesaro and Xencor
Oct 22, 2018
Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress
Oct 16, 2018
CStone Receives U.S. IND Approval for PD-L1 Antibody CS1001
Oct 10, 2018
Immune Checkpoint Inhibitors Market is Anticipated to Cross US$ 25 Billion by 2022 Due to Increasing Prevalence of Cancer and Immune Diseases: Radiant Insights, Inc.
Oct 09, 2018
Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Sep 18, 2018
Immune Checkpoint Inhibitors Market to Reach $56.53 Bn by 2025: Allied Market Research
Aug 28, 2018
Global PD-1 and PD-L1 Inhibitors Market 2018-2022: PD-1 and PD-L1 Inhibitors Market by Value, Treatment and Cancer Type - Focus on China, US & Globe
Jul 10, 2018
Ovarian Cancer Drugs Market Size Worth $4.5 Billion by 2022: Grand View Research, Inc.
Jun 13, 2018
CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001
Feb 13, 2018
Phase II trial demonstrates activity of durvalumab in patients with recurrent or metastatic head and neck cancer